We aimed to determine whether combining serum alpha‐fetoprotein (AFP) level with
hepatocellular carcinoma (HCC) tumor burden would allow better stratification of …

Alpha-fetoprotein (AFP) is the main tumor biomarker available for the management of
hepatocellular carcinoma (HCC). Although it is neither a good screening test nor an …

Hypothesis An elevated serum α-fetoprotein (AFP) level before orthotopic liver transplant
(OLT) is predictive of mortality after OLT for hepatocellular carcinoma (HCC). Design …

Background Many patients with hepatocellular carcinoma (HCC) who undergo liver
transplantation (LT) subsequently develop tumor recurrence; this is the main factor affecting …

Liver transplantation (LT) for cirrhotic/Hepatocellular carcinoma (HCC) is associated with
reduced survival in patients with poor histological features. Preoperative levels of …

Serum alpha‐fetoprotein (AFP) has been increasingly recognized as a marker for a poor
prognosis after liver transplantation (LT) for hepatocellular carcinoma (HCC). Many …

BACKGROUND & AIMS: Liver transplantation is a recognized treatment for selected patients
with hepatocellular carcinoma (HCC), but transplant criteria still need to be refined …

Growing evidence suggests that pretransplant alpha‐fetoprotein (AFP) predicts outcomes of
hepatocellular carcinoma (HCC) patients treated with liver transplantation. We aimed to …

Importance Serum α-fetoprotein (AFP) is a biomarker for hepatocellular carcinomas (HCCs)
associated with a more aggressive tumor phenotype and inferior outcomes after a liver …

Background Serum α-fetoprotein concentration (AFP) might be a useful addition to
morphologic criteria for selecting patients with hepatocellular carcinoma (HCC) for liver …